AK117/Placebo with Azacitidine

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study of AK117/Placebo in Combination With Azacitidine in Patients With Newly Diagnosed Higher-risk Myelodysplastic Syndromes

Near Add Your Location

Sorting 14 by

Center of Excellence

Ohio State University Comprehensive Cancer Center
James Cancer Hospital and Solove Research Institute
Columbus, OH
  • Accepting patients

Center of Excellence

UNC Lineberger Comprehensive Cancer Center
University of North Carolina
Chapel Hill, NC
  • Accepting patients

Center of Excellence

The University of Texas Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center
Dallas, TX
  • Accepting patients

Center of Excellence

Smilow Cancer Hospital at Yale New Haven
New Haven, CT
  • Accepting patients
American Oncology Partners of Maryland (Bethesda)
The Center for Cancer & Blood Disorders - Bethesda
Bethesda, MD
  • Accepting patients
Alvin J. Siteman Cancer Center
Washington University Medical Campus
St. Louis, MO
  • Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.